Boston Scientific Corporation vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF — how do they compare? Boston Scientific Corporation trades at $43.55 (market cap $66.37B), while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF trades at $40.6. The key difference: YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | QDTY | |
|---|---|---|
Market Cap | $66.37B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $108.14 | $46.71 |
52-Week Low | $42.63 | $36.57 |
Enterprise Value | $75.94B | — |
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
QDTY trades at $40.43, down 1.84% today amid bearish technical signals. The stock faces selling pressure with moving averages indicating a downtrend, while oscillators remain neutral. Recent weekly dividend announcements from YieldMax ETFs highlight the fund's distribution strategy, though key financial ratios are currently unavailable for fundamental assessment.
The outlook remains cautious with technical indicators pointing to continued weakness. Investment opportunity hinges on the ETF's ability to maintain consistent distributions, while risks include market volatility and the absence of clear valuation metrics. Investors should await updated financial disclosures for fundamental clarity.
Trailing returns across standard periods
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →QDTY is an actively managed ETF that employs a synthetic covered call strategy on the Nasdaq-100 Index using zero-days-to-expiration (0DTE) options. It aims to generate high weekly income by selling daily call options, providing limited participation in the index's upside while remaining fully exposed to its downside risk.
Read more on QDTY →